Cureseq

About:

CureSeq’s mission is to revolutionize next-generation sequencing in the oncology space by making it more affordable.

Twitter/X: CureSeq

Top Investors: TSVC, Venture Leader Group

Description:

CureSeq’s mission is to revolutionize next-generation sequencing in the oncology space by making it more affordable, offering faster time to results with a comprehensive solution. They offer products to advance your research endeavors, and will open their services shortly. Turnaround time using their products is 48 hours from extraction through generating clinically relevant mutations. CureSeq’s technology is born out of the Applied Genomics Thoracic Oncology Lab of Dr. Il-Jin Kim at UCSF.

Total Funding Amount:

$700000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Brisbane, California, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)cureseq.com

Founders:

Biao He, Dr. David Jablons, IL-Jin Kim

Number of Employees:

11-50

Last Funding Date:

2016-08-12

IPO Status:

Private

Industries: